Which peptides were in the July 2026 compounding vote?

BPC-157, TB-500, KPV and MOTS-c were voted suitable for the compounding list. Each still needs the final rule before pharmacies can act.

Live tracker · updated 22 Sep 2026

Compounding
status.

Q: Did the FDA approve BPC-157?

No. An FDA advisory panel voted in July 2026 to allow licensed pharmacies to COMPOUND BPC-157 — a different thing from drug approval. If the rule is finalized, prescribers could order it from compounding pharmacies; it still would not be an approved medicine.

Q: When can you get BPC-157 from a pharmacy legally?

Not yet. The panel vote is advisory; the final rule is expected around mid-2027. Until it lands, no US pharmacy can legally dispense BPC-157, and everything sold online remains a research chemical.

Q: What changes if compounding is allowed?

The grey market's main excuse disappears: a physician could prescribe and a licensed US pharmacy could dispense, with tested purity and real labels. Prices and access would look like sermorelin does today.

The FDA panel said yes to pharmacy compounding of BPC-157, TB-500, KPV and MOTS-c. This page tracks the distance between that vote and a legal vial — as it closes.

Where each peptide stands

BPC-157 — voted suitable, awaiting final rulePanel vote July 2026 · today still research-chemical only · drug page

TB-500 — voted suitable, awaiting final ruleSame vote, same distance · drug page

KPV — voted suitable, awaiting final ruleThe quiet winner: gut and skin protocols would go legit · drug page

MOTS-c — voted suitable, awaiting final ruleEnergy and metabolic lane · drug page

A compounding listing is not drug approval. It would let licensed pharmacies fill prescriptions — purity tested, labels real — while the molecule itself stays unapproved. Think sermorelin's status today.

What changed

22 Sep 2026 — tracker launchedStatus: advisory vote passed, final rule pending, expected around mid-2027

Jul 2026 — the voteFDA Pharmacy Compounding Advisory Committee voted BPC-157, TB-500, KPV and MOTS-c suitable for the compounding list

2023 to 2025 — the freeze yearsThe same peptides sat in FDA's risk category, pushing the entire market grey

Next milestone we watch: the proposed rule entering the Federal Register. The moment it moves, this page moves.

Until the rule lands

Nothing is legal yet. Vials sold online today are research chemicals: no purity testing you can verify, no pharmacy, no recourse. The vote did not change that — it only set a clock.

What is actually safe todayThe honest safety guide, peptide by peptide

Read the safety guide

Legal this whole time

Sermorelin, tesamorelin, GLP-1 medicines and several others already run through licensed pharmacies with a prescription — no waiting for 2027.

See the approved list

Common questions

Did the FDA approve BPC-157?

No. The panel voted to allow pharmacy COMPOUNDING — a different thing from approval. If finalized, prescribers could order it from compounding pharmacies; the molecule itself stays unapproved.

When can you get BPC-157 from a pharmacy legally?

Not yet. The vote is advisory; the final rule is expected around mid-2027. Until then no US pharmacy can dispense it, and everything online remains a research chemical.

Which peptides were in the July 2026 vote?

BPC-157, TB-500, KPV and MOTS-c — all four voted suitable for the compounding list, all four awaiting the same final rule.

What changes if compounding is allowed?

The grey market loses its main excuse: a physician prescribes, a licensed US pharmacy dispenses, purity is tested, labels are real. Access would look like sermorelin's today.

Get the update when it moves.

One email when the rule advances — the subscribe box below catches every tracker change.

All updates

Compoundingstatus.